Tumorad® enables internal radiation treatment of tumors, so called radionuclide therapy (RNT). The aim is to bring precision RNT for effective treatment of cancer, stand-alone or in combination with other therapies. Clinical development of Tumorad® includes a theranostic imaging approach for selection of patients with high likelihood of response in tumor indications with documented high EPR-effect. Tumorad® provides the possibility of one radiopharmaceutical treatment against several types of solid soft tissue tumors, as monotherapy or in combination with other treatments. In the Tumorad® project, nanoparticles are loaded with radioactive isotopes providing the opportunity for radionuclide therapy against cancer. The candidate drug 177 Lu-SN201 has been optimally designed for physiological targeting by means of the EPR effect. Preclinical results from different tumor models confirm accumulations in tumors, inhibited tumor growth and extended survival. Benefits of Tumorad® - Tumor selectivity: The local accumulation of Tumorad® opens for delivery of an adapted radiation dose sufficient to treat the tumors while minimizing undesirable effects on surrounding tissue. This also allows treatment of several types of solid soft tissue tumors. - Local radiation: The advantage of radiopharmaceutical therapy compared to external beam radiation is its ability to selectively deliver radioactivity to tumors and thereby irradiate multiple soft tissue tumors or metastases simultaneously. The technology also enables irradiation of tumors that could not otherwise be treated with external beam radiation, such as deeper situated tumors or tumors adjacent to vital organs. - Easy preparation: Easy radiolabeling and preparation for facilitated handling in the clinic. - Individualized treatment: Based on dosimetry analysis following a diagnostic Tumorad® dose, it is possible to calculate tumor versus non-tumor uptake and therefore the likelihood of treatment success for an individual patient. - Complementary treatment: Enables combination treatments with other therapies for optimised efficacy
SpagoPix aims to bring a nanomedical contrast agent for magnetic resonance tomography (MRI). Available clinical results in endometriosis and breast cancer support the platform technology and provide for improved imaging precision and visualization of endometriosis and tumors than what is possible today. Initial clinical development is focused on indications with a clear medical need for improved imaging. SpagoPix has the potential of significantly improving diagnostics through earlier, enhanced and more precise visualization. In SpagoPix we develop a gadolinium-free MRI contrast agent for precision imaging of endometriosis and cancer. The SpagoPix project aims to launch a ground-breaking gadolinium-free MRI contrast agent, pegfosimer manganese, for improved visualization of tumors and other lesions. Unlike the conventional low molecular-weight MRI contrast agents, which enhance healthy tissue as well as diseased and therefore results in a relatively high proportion of false positive findings, pegfosimer manganese is designed to selectively accumulate in diseased tissue. This could contribute to improved precision in MRI scans, e.g. for suspected endometriosis and cancers. Benefits of SpagoPix - Controlled build-up of MRI signal: allows high resolution images of the tumor to be captured. The MRI signal from SpagoPix is built up over several hours which is an advantage when several images need to be captured or when an MRI scan is performed. This is not possible when gadolinium-based contrast agents are used since they leave the body in a couple of minutes. - Exceptional enhancement: SpagoPix has several times higher relaxivity in measurements than other contrast agents on the market. New data is showing that the relaxivity of the SpagoPIx product candidate SN132D is among the highest measured for an MRI contrast agent. - Tumor selectivity: Thanks to the combination of the tumor-selective mode of action and the high signal strength, SpagoPix can provide a clearer and more precise image of the tumor. This reduces the risk of so-called false positive findings, which is a significant improvement over the existing contrast agents that often result in misdiagnosis. - Free from gadolinium: The risk of adverse effects from use of gadolinium, foreign to the body, is eliminated. SpagoPix uses manganese to enhance the signal in an MRI examination. Manganese is an essential element that occurs in many of our most common food and is needed to maintain good health. When manganese is bound to other substances as in SpagoPix, there is significantly reduced risk of negative impact due to high dosage.
CATEGORY
